MTHFR C677T and A1298C polymorphisms as predictors of radiotherapy response in head and neck squamous cell carcinoma

• Main Author: Anders, Q. S.
• Publication Date: 2015
• Other Authors: Stur, E., Agostini, Lidiane Pignaton, Garcia, F. M., Reis, R. S., Santos, J. A., Mendes, S. O., Maia, L. L., Peterle, G. T., Stange, V., Carvalho, M. B., Tajara, E. H., Santos, Marcelo dos, Silva-Conforti, A. M. A., Louro, I. D.
• Format: Article
• Language: eng
• Source: Repositório Institucional da UFRN
• dARK ID: ark:/41046/001300001n01r
• Download full: https://repositorio.ufrn.br/handle/123456789/31481
• topic: MTHFR; Head and neck cancer; Radiotherapy

The C677T and A1298C polymorphisms in methylenetetrahydrofolate reductase (MTHFR), which regulates the release of active folate in the body, may have reduced activity. Given that folate participates in important intracellular pathways, such as nucleotide synthesis and biomolecule methylation, it seems plausible that patients with head and neck squamous cell carcinoma (HNSCC) may respond differently to radiotherapy treatments, based on genetic polymorphisms. Therefore, this study sought to understand the role of these polymorphisms in HNSCC patient radiotherapy response. Genotypes were detected by PCR-RFLP after extraction of DNA from peripheral blood lymphocytes. Survival curves were analyzed by the KaplanMeier model, and significant differences were analyzed by the Wilcoxon test. Response to radiotherapy in patients with laryngeal SCC was significantly associated with the MTHFR C677T polymorphism (P = 0.030). Indeed, the presence of at least one T allele decreases the mortality rate up to 3-fold. Therefore, we propose that MTHFR C677T may represent a putative biomarker for radiotherapy prognosis in laryngeal SCC patients